Novo Nordisk A/S (NYSE:NVO) Stock Rating Upgraded by BNP Paribas

BNP Paribas upgraded shares of Novo Nordisk A/S (NYSE:NVO) to a strong-buy rating in a research note published on Monday,Zacks.com reports.

NVO has been the subject of several other reports. BMO Capital Markets lowered their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $150.40.

Novo Nordisk A/S Trading Down 0.2 %

NYSE NVO opened at $108.96 on Monday. The stock has a 50-day simple moving average of $111.82 and a 200 day simple moving average of $127.46. The company has a market capitalization of $488.96 billion, a PE ratio of 35.26, a P/E/G ratio of 1.41 and a beta of 0.40. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. American Trust boosted its position in Novo Nordisk A/S by 139.1% during the third quarter. American Trust now owns 12,725 shares of the company’s stock valued at $1,515,000 after purchasing an additional 7,402 shares during the last quarter. Tri Ri Asset Management Corp acquired a new position in Novo Nordisk A/S during the third quarter valued at approximately $17,276,000. Peapack Gladstone Financial Corp boosted its position in Novo Nordisk A/S by 17.2% during the third quarter. Peapack Gladstone Financial Corp now owns 28,156 shares of the company’s stock valued at $3,353,000 after purchasing an additional 4,122 shares during the last quarter. Synovus Financial Corp boosted its position in Novo Nordisk A/S by 5.2% during the third quarter. Synovus Financial Corp now owns 54,697 shares of the company’s stock valued at $6,513,000 after purchasing an additional 2,684 shares during the last quarter. Finally, Optimist Retirement Group LLC boosted its position in Novo Nordisk A/S by 4.3% during the third quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company’s stock valued at $327,000 after purchasing an additional 112 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.